Authors' objectives: This is the pharmaceutical Joint Assessment PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). In August, 2020, the European Commission granted marketing authorisation for pretomanide (pretomanid FGK) in combination with bedaquiline and linezolid for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). Publication of this PTJA14 was postponed by 5 weeks due to the unavailability of the EPAR. This Joint Assessment aims to compare the clinical effectiveness and safety of pretomanid in the target patient populations with relevant comparators, according to the national requirements of EUnetHTA partners.

Project Status: Completed

URL for project: https://eunethta.eu/ptja14/

Year Published: 2020

URL for published report: https://eunethta.eu/ptja14/

Requestor: HTA agencies

English language abstract: An English language summary is available

Publication Type: Rapid Review

Organisation Name: European Network for Health Technology Assessment

Contact Email: eunethta@zinl.nl

Copyright: CC-BY-NC: You may copy, distribute, display, perform, and modify and use the EUnetHTA work for any purpose other than commercially unless you get your permission first.